Blocking the PD‐1/PD‐L1 interaction enhances the antitumour effects of imatinib by rescuing exhausted CD8+ T cells in PD‐L1‐positive GIST cells, particularly through the PI3K/Akt/mTOR pathway [71]. This evidence concerns the gene MTOR and gastrointestinal stromal tumor.